Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 1 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neurofibrosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Plasma Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × ixazomib × Clear all
NCT01887587 2020-01-22

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Medical College of Wisconsin

Phase 1 Terminated
5 enrolled 9 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00932698 2019-08-07

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Takeda

Phase 1 Completed
60 enrolled 34 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡